CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
|Brand Name||Zykadia (Resubmission)|
|Indication||Non-Small Cell Lung Cancer|
|Funding Request||For treatment as monotherapy in patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have progressed on or who were intolerant to crizotinib|
|Pre Noc Submission||No|
|NOC Date||March 27, 2015|
|Manufacturer||Novartis Pharmaceuticals Canada Inc.|
|Sponsor||Novartis Pharmaceuticals Canada Inc.|
|Submission Date||October 19, 2016|
|Submission Deemed Complete||November 2, 2016|
|Prioritization Requested||Not Requested|
|Stakeholder Input Deadline ‡||November 2, 2016|
|Check-point meeting||December 8, 2016|
|pERC Meeting||February 16, 2017|
|Initial Recommendation Issued||March 3, 2017|
|Feedback Deadline ‡||March 17, 2017|
|Final Recommendation Issued||March 21, 2017|
|Notification to Implement Issued||April 5, 2017|
|Therapeutic Area||metastatic non-small cell lung cancer|
|Recommendation Type||Reimburse with clinical criteria and/or conditions|
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.